{"id":692347,"date":"2022-10-05T08:18:56","date_gmt":"2022-10-05T12:18:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/"},"modified":"2022-10-05T08:18:56","modified_gmt":"2022-10-05T12:18:56","slug":"iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/","title":{"rendered":"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting"},"content":{"rendered":"<h2>\nOral Presentation of C-144-01 Trial Cohorts 2 and 4<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">SAN CARLOS, Calif., Oct.  05, 2022  (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the <a href=\"https:\/\/www.sitcancer.org\/2022\/home\" rel=\"nofollow noopener\" target=\"_blank\">Society for Immunotherapy of Cancer\u2019s (SITC) 37<sup>th<\/sup> Annual Meeting<\/a> in Boston, Massachusetts, November 8-12, 2022. The details of the posters and presentations are as follows:<\/p>\n<p>\n        <strong>Title: <\/strong><br \/>\n        <strong>Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study)<\/strong><br \/>\n        <br \/>\n        <strong>Authors:<\/strong> A. Sarnaik, <em>et al<\/em><br \/><strong>Presentation Type:<\/strong> Rapid Oral Abstracts and Poster<br \/><strong>Session Date and Time: <\/strong>November 10, 2022, Concurrent Session 105 (11:55 a.m. \u2013 12:55 p.m. ET) and Poster Hall (1 p.m. \u2013 9:00 p.m. ET)<br \/><strong>Abstract ID:<\/strong> 789<\/p>\n<p>\n        <strong>Title: <\/strong><br \/>\n        <strong>Trial in progress: A phase 1\/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1\u2013inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC<\/strong><br \/>\n        <br \/>\n        <strong>Authors:<\/strong> A. Betof Warner, <em>et al<\/em><br \/><strong>Presentation Type:<\/strong> Poster<br \/><strong>Session Date and Time:<\/strong> November 10, 2022, 9:00 a.m. \u2013 9:00 p.m. ET, Poster Hall<br \/><strong>Abstract ID:<\/strong> 783<\/p>\n<p>Iovance will host a webcast and conference call on Thursday, November 10, 2022 at 4:30 p.m. ET to discuss the pooled analysis of Cohorts 2 and 4 of the C-144-01 study of lifileucel in advanced melanoma. Iovance senior leadership will be joined by key opinion leaders and principal investigators. The live and archived webcast will be available in the Investors section of the company\u2019s website at <a href=\"http:\/\/www.iovance.com\" rel=\"nofollow noopener\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>\n        <strong>About\u00a0Iovance Biotherapeutics, Inc.<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.iovance.com\/\" rel=\"nofollow noopener\" target=\"_blank\">Iovance Biotherapeutics<\/a> aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system\u2019s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The <a href=\"https:\/\/www.iovance.com\/our-science\/til-platform\/\" rel=\"nofollow noopener\" target=\"_blank\">Iovance TIL platform<\/a> has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit <a href=\"http:\/\/www.iovance.com\" rel=\"nofollow noopener\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain matters discussed in this press release are \u201cforward-looking statements\u201d of Iovance Biotherapeutics, Inc. (hereinafter referred to as the \u201cCompany,\u201d \u201cwe,\u201d \u201cus,\u201d or \u201cour\u201d) within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management\u2019s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled &#8220;Risk Factors&#8221; in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (\u201cFDA\u201d) or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; whether clinical trial results from our pivotal studies and cohorts may support registration and approval by the FDA; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA (including from the recent pre-BLA meeting with the FDA); the risk that the rolling BLA submission for lifileucel in metastatic melanoma may take longer than expected; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.<\/p>\n<p>\n        <strong>CONTACTS<\/strong>\n      <\/p>\n<p>\n        <strong>Iovance Biotherapeutics, Inc.:<\/strong>\n      <\/p>\n<p>Sara Pellegrino, IRC<br \/>Senior Vice President, Investor Relations &amp; Corporate Communications<br \/>650-260-7120 ext. 264<br \/><a href=\"mailto:Sara.Pellegrino@iovance.com\" rel=\"nofollow noopener\" target=\"_blank\">Sara.Pellegrino@iovance.com<\/a><\/p>\n<p>Jen Saunders<br \/>Director, Investor Relations &amp; Public Relations<br \/>267-485-3119<br \/><a href=\"mailto:Jen.Saunders@iovance.com\" rel=\"nofollow noopener\" target=\"_blank\">Jen.Saunders@iovance.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTg2ZjBmYjMtODA4OC00MjZiLWFhYzAtZTA5YmNmYTFlZTNkLTEwMzA3Njk=\/tiny\/Iovance-Biotherapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oral Presentation of C-144-01 Trial Cohorts 2 and 4 SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting in Boston, Massachusetts, November 8-12, 2022. The details of the posters and presentations are as follows: Title: Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study) Authors: A. Sarnaik, et alPresentation Type: Rapid Oral Abstracts and PosterSession Date and Time: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692347","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Oral Presentation of C-144-01 Trial Cohorts 2 and 4 SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting in Boston, Massachusetts, November 8-12, 2022. The details of the posters and presentations are as follows: Title: Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study) Authors: A. Sarnaik, et alPresentation Type: Rapid Oral Abstracts and PosterSession Date and Time: &hellip; Continue reading &quot;Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T12:18:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting\",\"datePublished\":\"2022-10-05T12:18:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/\"},\"wordCount\":1092,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/\",\"name\":\"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=\",\"datePublished\":\"2022-10-05T12:18:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/","og_locale":"en_US","og_type":"article","og_title":"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting - Market Newsdesk","og_description":"Oral Presentation of C-144-01 Trial Cohorts 2 and 4 SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) cell therapies at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting in Boston, Massachusetts, November 8-12, 2022. The details of the posters and presentations are as follows: Title: Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study) Authors: A. Sarnaik, et alPresentation Type: Rapid Oral Abstracts and PosterSession Date and Time: &hellip; Continue reading \"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T12:18:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","datePublished":"2022-10-05T12:18:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/"},"wordCount":1092,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/","name":"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=","datePublished":"2022-10-05T12:18:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTQyMyM1MTg3OTQwIzIwMTkxOTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-to-present-clinical-data-for-lifileucel-tumor-infiltrating-lymphocyte-til-therapy-in-advanced-melanoma-at-society-for-immunotherapy-of-cancers-sitc-37th-annual-mee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692347"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692347\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}